A Case of Lung Adenocarcinoma with Postoperative Recurrence of Multiple Bone Metastases that Showed a Gradual Complete Response to Combined Administration of Erlotinib and Zoledronic Acid
Restricted accessResearch articleFirst published online March, 2014
A Case of Lung Adenocarcinoma with Postoperative Recurrence of Multiple Bone Metastases that Showed a Gradual Complete Response to Combined Administration of Erlotinib and Zoledronic Acid
We describe a case of lung adenocarcinoma with multiple postoperative bone metastases that showed a gradual but complete response to combined administration of erlotinib and zoledronic acid. A 76-year-old man with moderately differentiated adenocarcinoma underwent a radical left upper lobectomy and mediastinal lymph node dissection. Three and a half years after the operation, serum carcinoembryonic antigen (CEA) was elevated and 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) revealed multiple bone metastases. Pretreatment evaluation of EGFR mutations in the resected primary adenocarcinoma specimen showed an L858R mutation in exon 21. Gefitinib was started as first-line treatment. However, evaluation 1 month after administration revealed progressive disease. Erlotinib was started as second-line treatment, and evaluation 1 month after administration revealed that the disease was stable. Administration of zoledronic acid was then begun with continuation of erlotinib. After 2 courses of zoledronic acid, the serum CEA level had not changed but the maximum standardized uptake values of each region uniformly decreased. Furthermore, the uptake of 18FDG completely disappeared after 6 courses. Subsequently, the serum CEA level continued to decrease and the disappearance of 18FDG uptake was confirmed after 10 courses (12 months after initiation of erlotinib administration). Our results suggest that the combined administration of both drugs is effective against bone metastases.
RosenL.S., GordonD., TchekmedyianN.S., YanagiharaR., HirshV., KrzakowskiM., PawlickiM., De SouzaP., ZhengM., UrbanowitzG., ReitsmaD., SeamanJ.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial.Cancer, 100: 2613–2621, 2004.
MitsudomiT., MoritaS., YatabeY., NegoroS., OkamotoI., TsurutaniJ., SetoT., SatouchiM., TadaH., HirashimaT., AsamiK., KatakamiN., TakadaM., YoshiokaH., ShibataK., KudohS., ShimizuE., SaitoH., ToyookaS., NakagawaK., FukuokaM.: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol, 11: 121–128, 2009.
5.
MaemondoM., InoueA., KobayashiK., SugawaraS., OizumiS., IsobeH., GemmaA., HaradaM., YoshizawaH., KinoshitaI., FujitaY., OkinagaS., HiranoH., YoshimoriK., HaradaT., OguraT., AndoM., MiyazawaH., TanakaT., SaijoY., HagiwaraK., MoritaS., NukiwaT.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med, 362: 2380–2388, 2010.
6.
FukuokaM., WuY.L., ThongprasertS., SunpaweravongP., LeongS.S., SriuranpongV., ChaoT.Y., NakagawaK., ChuD.T., SaijoN., DuffieldE.L., RukazenkovY., SpeakeG., JiangH., ArmourA.A., ToK.F., YangJ.C., MokT.S.: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).J Clin Oncol, 29: 2866–2874, 2011.
7.
JanneP.A., WangX., SocinskiM.A., CrawfordJ., StinchcombeT.E., GuL., CapellettiM., EdelmanM.J., Villalona-CaleroM.A., KratzkeR., VokesE.E., MillerV.A.: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.J Clin Oncol, 30: 2063–2069, 2012.
8.
KobayashiS., BoggonT.J., DayaramT., JanneP.A., KocherO., MeyersonM., JohnsonB.E., EckM.J., TenenD.G., HalmosB.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med, 352: 786–792, 2005.
9.
PaoW., MillerV.A., PolitiK.A., RielyG.J., SomwarR., ZakowskiM.F., KrisM.G., VarmusH.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLoS Med, 2: e73, 2005.
10.
KwakE.L., SordellaR., BellD.W., Godin-HeymannN., OkimotoR.A., BranniganB.W., HarrisP.L., DriscollD.R., FidiasP., LynchT.J., RabindranS.K., McGinnisJ.P., WissnerA., SharmaS.V., IsselbacherK.J., SettlemanJ., HaberD.A.: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Proc Natl Acad Sci U SA, 102: 7665–7670, 2005.
11.
KosakaT., YatabeY., EndohH., YoshidaK., HidaT., TsuboiM., TadaH., KuwanoH., MitsudomiT.: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.Clin Cancer Res, 12: 5764–5769, 2006.
12.
EngelmanJ.A., ZejnullahuK., MitsudomiT., SongY., HylandC., ParkJ.O., LindemanN., GaleC.M., ZhaoX., ChristensenJ., KosakaT., HolmesA.J., RogersA.M., CappuzzoF., MokT., LeeC., JohnsonB.E., CantleyL.C., JanneP.A.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science, 316: 1039–1043, 2007.
KairaK., NaitoT., TakahashiT., AyabeE., ShimoyamaR., KairaR., OnoA., IgawaS., ShukuyaT., MurakamiH., TsuyaA., NakamuraY., EndoM., YamamotoN.: Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.Lung Cancer, 68: 99–104, 2010.
BaselgaJ., RischinD., RansonM., CalvertH., RaymondE., KiebackD.G., KayeS.B., GianniL., HarrisA., BjorkT., AverbuchS.D., FeyereislovaA., SwaislandH., RojoF., AlbanellJ.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.J Clin Oncol, 20: 4292–4302, 2002.
17.
HidalgoM., SiuL.L., NemunaitisJ., RizzoJ., HammondL.A., TakimotoC., EckhardtS.G., TolcherA., BrittenC.D., DenisL., FerranteK., Von HoffD.D., SilbermanS., RowinskyE.K.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.J Clin Oncol, 19: 3267–3279, 2001.
18.
SatohH., IshikawaH., OharaG., KikuchiN., SekizawaK.: Prolonged response to gefitinib in bone metastasis.Med Oncol, 26: 101–102, 2009.
19.
YamashitaY., AokiT., HanagiriT., YoshiiC., MukaeH., UramotoH., KorogiY.: Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response.Skeletal Radiol, 41: 409–414, 2011.
20.
NormannoN., De LucaA., AldinucciD., MaielloM.R., MancinoM., D'AntonioA., De FilippiR., PintoA.: Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis.Endocr Relat Cancer, 12: 471–482, 2005.
21.
RoelofsA.J., ThompsonK., GordonS., RogersM.J.: Molecular mechanisms of action of bisphosphonates: current status.Clin Cancer Res, 12: 6222s–6230s, 2006.
22.
ChangJ.W., HsiehJ.J., ShenY.C., YehK.Y., WangC.H., LiY.Y., HsuT.: Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.Cancer Lett, 278: 17–26, 2009.
23.
GnantM., ClezardinP.: Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.Cancer Treat Rev, 38: 407–415, 2011.
24.
ZarogoulidisK., BoutsikouE., ZarogoulidisP., EleftheriadouE., KontakiotisT., LithoxopoulouH., TzanakakisG., KanakisI., KaramanosN.K.: The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.Int J Cancer, 125: 1705–1709, 2009.
